Lack of genetic evidence that fatty liver disease predisposes to COVID-19.
作者信息
Valenti Luca, Jamialahmadi Oveis, Romeo Stefano
机构信息
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy; Translational Medicine - Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
出版信息
J Hepatol. 2020 Sep;73(3):709-711. doi: 10.1016/j.jhep.2020.05.015. Epub 2020 May 20.
Abstract
摘要
相似文献
1
Lack of genetic evidence that fatty liver disease predisposes to COVID-19.缺乏脂肪肝疾病易引发2019冠状病毒病的基因证据。
J Hepatol. 2020 Sep;73(3):709-711. doi: 10.1016/j.jhep.2020.05.015. Epub 2020 May 20.
2
No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.在代谢相关脂肪性肝病中，没有证据表明严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的肝脏摄取增加。
J Hepatol. 2020 Sep;73(3):717-718. doi: 10.1016/j.jhep.2020.04.035. Epub 2020 Apr 30.
3
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.代谢功能障碍相关脂肪性肝病且纤维化评分升高的患者感染新型冠状病毒肺炎后出现重症的风险。
Gut. 2020 Aug;69(8):1545-1547. doi: 10.1136/gutjnl-2020-321611. Epub 2020 May 15.
4
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.致编辑的信：肥胖作为代谢相关脂肪性肝病患者中COVID-19病情更严重的危险因素
Metabolism. 2020 Jul;108:154256. doi: 10.1016/j.metabol.2020.154256. Epub 2020 Apr 29.
5
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study.新型冠状病毒肺炎患者的非酒精性脂肪性肝病：一项回顾性研究。
J Hepatol. 2020 Aug;73(2):451-453. doi: 10.1016/j.jhep.2020.03.044. Epub 2020 Apr 8.
6
Commentary: Obesity: The "Achilles heel" for COVID-19?评论：肥胖：新冠病毒的“阿喀琉斯之踵”？
Metabolism. 2020 Jul;108:154251. doi: 10.1016/j.metabol.2020.154251. Epub 2020 Apr 27.
7
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.致编辑的信：肥胖作为代谢相关脂肪性肝病患者感染 COVID-19 时病情更严重的风险因素。
Metabolism. 2020 Jul;108:154244. doi: 10.1016/j.metabol.2020.154244. Epub 2020 Apr 19.
8
Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'.回复：“无证据表明代谢相关脂肪性肝病中严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的肝脏摄取增加” 。
J Hepatol. 2020 Sep;73(3):718-719. doi: 10.1016/j.jhep.2020.04.039. Epub 2020 May 6.
9
COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?新型冠状病毒肺炎与药物性肝损伤：是个大问题还是小问题？
Arch Toxicol. 2020 Apr;94(4):1367-1369. doi: 10.1007/s00204-020-02734-1. Epub 2020 Apr 8.
10
A web-based group treatment for patients with alcoholic liver diseases at the time of the COVID-19 pandemic.在新冠疫情期间为酒精性肝病患者提供的基于网络的团体治疗。
Dig Liver Dis. 2020 Sep;52(9):956-957. doi: 10.1016/j.dld.2020.04.023. Epub 2020 May 6.
引用本文的文献
1
Global Epidemiological Impact of PNPLA3 I148M on Liver Disease.PNPLA3 I148M对肝脏疾病的全球流行病学影响。
Liver Int. 2025 Mar;45(3):e16123. doi: 10.1111/liv.16123. Epub 2024 Oct 7.
2
The pleiotropic approach to coronavirus disease-19 pathogenesis: The impact of liver diseases associated host genetic variants.冠状病毒病-19发病机制的多效性研究方法：肝脏疾病相关宿主基因变异的影响
Hepatol Forum. 2023 Dec 7;5(2):93-96. doi: 10.14744/hf.2023.2023.0018. eCollection 2024.
3
Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis.遗传因素预测 COVID-19 和 MAFLD 共病病程：综合分析。
Viruses. 2023 Aug 12;15(8):1724. doi: 10.3390/v15081724.
4
The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence.新型冠状病毒肺炎与代谢相关脂肪性肝病的关系：当前证据概述。
Viruses. 2023 Apr 27;15(5):1072. doi: 10.3390/v15051072.
5
COVID-19-related liver injury: Focus on genetic and drug-induced perspectives.新型冠状病毒肺炎相关肝损伤：聚焦遗传和药物诱导视角
World J Virol. 2023 Jan 25;12(1):53-67. doi: 10.5501/wjv.v12.i1.53.
6
COVID-19 and liver injury: An ongoing challenge.COVID-19 与肝损伤：持续面临的挑战。
World J Gastroenterol. 2023 Jan 14;29(2):257-271. doi: 10.3748/wjg.v29.i2.257.
7
Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?非酒精性脂肪性肝病与 COVID-19：无害伴侣还是疾病加剧因素？
World J Gastroenterol. 2023 Jan 14;29(2):367-377. doi: 10.3748/wjg.v29.i2.367.
8
Molecular mechanisms implicated in SARS-CoV-2 liver tropism.与 SARS-CoV-2 肝脏嗜性相关的分子机制。
World J Gastroenterol. 2022 Dec 28;28(48):6875-6887. doi: 10.3748/wjg.v28.i48.6875.
9
COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management.COVID-19 相关肝损伤：临床特征、病理生理机制和治疗管理。
Biomed Pharmacother. 2022 Oct;154:113568. doi: 10.1016/j.biopha.2022.113568. Epub 2022 Aug 17.
10
COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD.COVID-19 大流行：对 SARS-CoV-2 感染与 MAFLD 之间相互作用的深入了解。
Int J Biol Sci. 2022 Jul 11;18(12):4756-4767. doi: 10.7150/ijbs.72461. eCollection 2022.
本文引用的文献
1
No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.在代谢相关脂肪性肝病中，没有证据表明严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的肝脏摄取增加。
J Hepatol. 2020 Sep;73(3):717-718. doi: 10.1016/j.jhep.2020.04.035. Epub 2020 Apr 30.
2
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.在纽约市地区，5700 名因 COVID-19 住院的患者的特征、合并症和结局。
JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.
3
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study.新型冠状病毒肺炎患者的非酒精性脂肪性肝病：一项回顾性研究。
J Hepatol. 2020 Aug;73(2):451-453. doi: 10.1016/j.jhep.2020.03.044. Epub 2020 Apr 8.
4
COVID-19 and liver disease.新型冠状病毒肺炎与肝脏疾病
Liver Int. 2020 Jun;40(6):1278-1281. doi: 10.1111/liv.14470.
5
Liver injury during highly pathogenic human coronavirus infections.高致病性人冠状病毒感染期间的肝损伤。
Liver Int. 2020 May;40(5):998-1004. doi: 10.1111/liv.14435. Epub 2020 Mar 30.
6
Update on NAFLD genetics: From new variants to the clinic.非酒精性脂肪性肝病遗传学研究进展：从新的变异到临床应用。
J Hepatol. 2020 Jun;72(6):1196-1209. doi: 10.1016/j.jhep.2020.02.020. Epub 2020 Mar 4.
7
Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker.肝脏转录组学强调白细胞介素 32 作为新型非酒精性脂肪性肝病相关细胞因子和候选生物标志物。
Gut. 2020 Oct;69(10):1855-1866. doi: 10.1136/gutjnl-2019-319226. Epub 2020 Jan 30.
8
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver.非酒精性脂肪肝中肝脂肪与肝损伤和胰岛素抵抗的因果关系。
J Intern Med. 2018 Apr;283(4):356-370. doi: 10.1111/joim.12719. Epub 2017 Dec 27.
9
UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.英国生物银行：一个用于识别多种中老年复杂疾病病因的开放获取资源。
PLoS Med. 2015 Mar 31;12(3):e1001779. doi: 10.1371/journal.pmed.1001779. eCollection 2015 Mar.
Zotero 插件